WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Haematological, Renal, and Liver Function Parameters among Cirrhosis of Liver Patients: A Comprehensive Analysis

Preethi Kumari[1], Prof. Dr. Jaya Jain[2]

[1]Research Scholar, Malwanchal University, Indore
[2]ResearchSupervisor,Malwanchal University, Indore

Introduction

Cirrhosis of the liver is a chronic liver disease characterized by the replacement of healthy liver tissue with scar tissue, leading to impaired liver function. It is a progressive condition that can result from various etiologies such as chronic alcohol abuse, viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and autoimmune liver diseases. Cirrhosis not only affects the liver but also has profound implications for other organ systems, including the haematological and renal systems. In this article, we will explore the haematological, renal, and liver function parameters commonly observed in patients with cirrhosis of the liver, highlighting their clinical significance and implications.

Haematological Parameters in Cirrhosis

Cirrhosis of the liver often leads to alterations in haematological parameters due to the compromised liver function. These changes can include anemia, thrombocytopenia, and leukopenia. Anemia in cirrhosis is usually multifactorial and can result from reduced production of red blood cells, increased destruction, and impaired utilization of iron. The primary mechanisms contributing to anemia include decreased erythropoietin production, splenic sequestration, gastrointestinal bleeding, and nutritional deficiencies. Anemia can further worsen the clinical course of cirrhosis, leading to fatigue, worsened exercise capacity, and increased mortality.

Thrombocytopenia is another common haematological abnormality observed in cirrhosis. It is primarily caused by portal hypertension and hypersplenism, leading to a reduced platelet count. Thrombocytopenia in cirrhosis can contribute to an increased risk of bleeding, particularly in the presence of additional coagulation abnormalities.

Leukopenia, characterized by a decrease in the total white blood cell count, can also be observed in cirrhosis. The underlying mechanisms contributing to leukopenia are multifactorial and may include impaired bone marrow function, hypersplenism, sepsis, and drug-induced effects. Leukopenia in cirrhosis can result in increased susceptibility to infections and poor wound healing.

Renal Function Parameters in Cirrhosis

Renal dysfunction is a common complication of cirrhosis and is associated with significant morbidity and mortality. The pathogenesis of renal dysfunction in cirrhosis is complex and involves various mechanisms, including circulatory disturbances, activation of vasoactive systems, and systemic inflammation. The most severe form of renal dysfunction in cirrhosis is hepatorenal syndrome (HRS), which is characterized by renal vasoconstriction and reduced renal blood flow. HRS typically occurs in advanced stages of cirrhosis and carries a high mortality rate.

Apart from HRS, other renal function parameters are also affected in cirrhosis. Decreased glomerular filtration rate (GFR) is commonly observed, reflecting the impaired renal perfusion and renal hemodynamics associated with cirrhosis. The reduction in GFR can be progressive and is associated with an increased risk of developing complications such as electrolyte imbalances and fluid overload.

Serum creatinine levels, an important marker of kidney function, may be elevated in cirrhosis due to reduced creatinine clearance. However, creatinine alone may not accurately reflect renal function in cirrhosis, especially in the presence of muscle wasting and low muscle mass. Other markers, such as cystatin C and estimation equations, may provide a more reliable estimation of GFR in these patients.

Electrolyte imbalances are common in cirrhosis and can further contribute to renal dysfunction. Sodium and water retention, along with dilutional hyponatremia, are frequently observed. Additionally, imbalances in potassium, magnesium, and phosphate levels can occur, leading to various complications such as cardiac arrhythmias and muscle weakness.

Liver Function Parameters in Cirrhosis

Liver function tests (LFTs) are a set of blood tests that help assess liver health and function. In cirrhosis, LFTs can provide valuable information about the extent of liver damage and impairment of its synthetic and metabolic functions. Elevated serum bilirubin levels are a hallmark of cirrhosis and are a result of impaired bilirubin metabolism and reduced liver excretion capacity. Jaundice, a yellowish discoloration of the skin and mucous membranes, is often present in patients with cirrhosis.

Reduced albumin levels are another characteristic feature of cirrhosis. Albumin, synthesized by the liver, is responsible for maintaining oncotic pressure within blood vessels. The decreased synthesis of albumin in cirrhosis can result in peripheral edema and ascites formation. Additionally, impaired liver function can also affect the synthesis of other proteins, such as clotting factors, leading to impaired coagulation function. This can manifest as prolonged prothrombin time (PT) and increased bleeding tendencies.

Conclusion

Cirrhosis of the liver is a complex disease that affects multiple organ systems, including the haematological, renal, and liver systems. Understanding the haematological, renal, and liver function parameters in cirrhosis is crucial for the diagnosis, management, and prognosis of patients. Regular monitoring of these parameters can aid in identifying complications and guiding appropriate interventions. Collaborative efforts between hepatologists, hematologists, and nephrologists are essential to optimize the care of patients with cirrhosis, ensuring timely interventions to improve outcomes and quality of life. Further research is warranted to enhance our understanding of the underlying mechanisms and develop targeted therapies for the complications associated with cirrhosis.

Reference

1) Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet. 2001;40(9):685–94. https://doi.org/10.2165/00003088-200140090-00004.
2) Dickson SD, Salazar KC. Diagnosis and management of immediate hypersensitivity reactions to cephalosporins. Clin Rev Allerg Immunol. 2013;45:131–42. https://doi.org/10.1007/s12016-013-8367-x.
3) Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041–89. https://doi.org/10.2165/00003495-200262070-00005.
4) Roche Products Limited. Summary of product characteristics: Rocephin 2g powder for solution for injection or infusion. 2021. https://www.medicines.org.uk/emc/product/7932/smpc. Accessed 14 March 2022.
5) European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2022. Breakpoint tables for interpretations of MICs and zone diameters. 2022. https://www.eucast.org/clinical_breakpoints/. Accessed 14 Mar 2022.
6) Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations and management. Clin Microbiol Rev. 2015;28(3):603–61. https://doi.org/10.1128/CMR.00134-14.
7) Duncan CJA, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy, a review. Int J Clin Pharm. 2012;34:410–7. https://doi.org/10.1007/s11096-012-9637-z.
8) Duncan CJA, Evans TJ, Seaton RA. Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. J AntimicrobChemother. 2010;65(11):2483–4. https://doi.org/10.1093/jac/dkq339.
9) Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi D, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol. 2016;72:1003–11. https://doi.org/10.1007/s00228-016-2064-7.
10) Curran J, Lo J, Leung V, Brown K, Schwartz KL, Daneman N, Garber G, Wu JHC, Langford BJ. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect. 2022;28(4):479–90. https://doi.org/10.1016/j.cmi.2021.10.022.